Alcohol abuse and alcoholism represent substantial problems that affect a large portion of individuals throughout the world. Extensive research continues to be conducted in an effort to identify the biological basis of the reinforcing properties of alcohol in order to develop effective pharmacotherapeutic and behavioral interventions. One theory that has developed within the alcohol field over the past 4 decades postulates that the reinforcing properties of alcohol are due to the action of the metabolites/products of alcohol within the central nervous system (CNS). The most extreme version of this theory suggests that the biologically active metabolites/products of alcohol, created from the breakdown from alcohol, are the ultimate source of the reinforcing properties of alcohol. The contrary theory proposes that the reinforcing properties of alcohol are mediated completely through the interaction of the ethanol molecule with several neurochemical systems within the CNS. While there are scientific findings that offer support for both of these stances, the reinforcing properties of alcohol are most likely generated through a complex series of peripheral and central effects of both alcohol and its metabolites. Nonetheless, the development of a greater understanding for how the metabolites/products of alcohol contribute to the reinforcing properties of alcohol is an important factor in the development of efficacious pharmacotherapies for alcohol abuse and alcoholism. This chapter is intended to provide a historical perspective of the role of acetaldehyde (the first metabolite of alcohol) in alcohol reinforcement as well as review the basic research literature on the effects of acetaldehyde (and acetaldehyde metabolites/products) within the CNS and how these function with regard to alcohol reward.
Introduction
The vast majority of North Americans and Europeans will consume alcoholic beverages during their lives. The imbuement of alcoholic beverages is associated with the goal of obtaining a positive emotional state. The biological basis of the reinforcing properties of alcohol has not been completely established. A recurring theory in the alcohol field is that the reinforcing properties of alcohol are not produced by the ethanol (EtOH) molecule itself, but are dependent upon the action of EtOH metabolites/products. This stance asserts that EtOH is a pro-drug; EtOH is the base compound for biologically active metabolites/products that are the ultimate source of the reinforcing properties of EtOH. Therefore to understand the biological basis of alcoholism, there is a need to study the metabolites/products of EtOH. Figure 1 is a general schematic representing the main aspects of the central and peripheral metabolism of alcohol, and the pharmacological interactions of each metabolite/ condensation product, elucidated by research over the past century.
The principles underlying the 'EtOH is a pro-drug' theory are; 1) the concentrations required to observe EtOH effects in the CNS are too high for conventional pharmacological processes, 2) various behavioral/physiological consequences of alcohol consumption are observed for durations which surpass the bioavailability of EtOH within the system, and 3) metabolism of EtOH to acetaldehyde (ACD) within the CNS mediates most, if not all, of the CNS effects of EtOH. The contrary hypothesis holds that EtOH directly interacts with a number of neurotransmitter systems, and it is through these interactions that alcohol exerts its effects. The 'EtOH Alone' hypothesis asserts that ACD is aversive in the periphery and exists for such a short time period that it could not possibly mediate the persistent effects observed following alcohol intoxication.
Regardless of these opposing stances, genetic studies have clearly linked ACD metabolism with a risk for alcoholism. Specifically, genetic polymorphisms in alcohol dehydrogenase (ADH) and aldehyde dehydrogenase (ALDH) reduce the likelihood of the development of alcoholism (Edenberg, 2011) . Such polymorphisms are in genes that encode proteins that regulate the production and metabolism of alcohol and ACD, with both types of polymorphisms ultimately affecting ACD levels in the body. Peripheral increases in ACD levels produce an aversive state (e.g. flush, nausea, and sweating) which reduces the likelihood of continued EtOH consumption (Peng and Yin, 2009) . Recent research has established a polygenic contribution of the ADH gene cluster outlining a likely role for several ADH genes in the development of alcoholism (Frank et al., 2011) . Alterations in the ALDH2 gene, and the subsequent increase in ACD following EtOH consumption, have been thoroughly documented as protective in nature, with regard to the development of alcoholism amongst Asian populations (Ball, 2008) . Emerging evidence suggests that such protection may occur through two mechanisms: 1) an increase in the aversive effects of EtOH through increased ACD levels in the periphery and 2) a decrease in EtOH reward through a functional alteration in dopamine (DA) metabolism (Lu et al., 2010) . Inhibition of the ALDH2 gene acted to increase brain levels of tetrahydropapaveroline (THP; a tetrahydroisoquinoline) effectively decreasing cocaine induced DA signaling within the reward pathway of the brain (Yao et al., 2011) and it has been documented that higher levels of THP decrease EtOH consumption and preference (Duncan & Deitrich, 1980) . Thus, genetic polymorphisms may exhibit protective properties through a number of peripheral and central mechanisms working in tandem.
Currently, there are three pharmacotherapeutic agents for the treatment of alcoholism that are approved by the US FDA. These compounds have limited efficacy in preventing relapse to alcohol consumption or reducing on-going alcohol consumption (Bergmark, 2008) . Despite the decades of research, the biological basis of the effects of alcohol is not unequivocally known. The failure to develop efficacious pharmaceuticals for the treatment of alcoholism may be predicated upon the failure to fully determine the complex biological consequences of EtOH consumption, and that increasing the understanding of the role of ACD and ACD products in the reinforcing properties of EtOH may assist in the development of potential future pharmacotherapies for the treatment of alcoholism. The intent of this review is to provide a historical perspective of ACD and review the basic research literature of the effects of ACD (and ACD metabolites) within the CNS.
Relevance and History of Acetaldehyde and Alcoholism
Alcoholism represents a substantial health issue in the United States and throughout the world. Currently, there are over 18 million Americans that abuse alcohol or are classified as alcohol dependent (NIAAA, 2008) . The World Health Organization has estimated that 140 million individuals throughout the world could be currently diagnosed with alcohol dependency (WHO, 2003) . For perspective, 140 million is approximately the population of Russia, the 9 th largest country in the world by population. In the United States and Eastern Europe, between 10 and 20% of males, and 5 to 10% of females, could be diagnosed with alcohol dependency (WHO, 2003) .
Like the majority of drugs of abuse, the reinforcing action of alcohol primarily occurs within the dopamine (DA) reward pathway, which originates in the ventral midbrain (ventral tegmental area; VTA) and projects to forebrain regions that include the nucleus accumbens (Acb) and the medial prefrontal cortex (mPFC; Koob et al., 1998; McBride et al., 1999) . Furthermore, manipulation of the DA, serotonin (5-HT), γ-aminobutyric acid (GABA), opioid, and glutamate (GLU) systems within the DA reward pathway, or within structures or areas that project to the DA reward pathway, has been found to effectively alter alcoholrelated behaviors in preclinical research (Vengeliene et al., 2008; Koob et al., 1998) .
Over the past century, researchers have described the aversive effects of alcohol following the ingestion of a number of compounds which, in turn, significantly affected alcohol related behaviors in both preclinical as well as clinical populations. Koelsch (1914) described a number of transitory symptoms following alcohol consumption in factory workers manufacturing calcium cyanamide, an organic compound originally synthesized for the production of metals. Following even a minimal intake of alcohol, individuals exposed to calcium cyanamide would become "hypersensitive to alcohol" and experience flushing (redness) of the face, headaches, shortness of breath, and increased heart rate eventually followed by fatigue (Koelsch, 1914) . Chifflot (1916) reported that consumption of an ink cap mushroom (coprinus atramentarius) prior to consuming alcohol displayed a similar 'aversive' reaction to EtOH consumption. Coprine, an amino acid in the ink cap mushroom, was determined to produce the aversive physical responses to alcohol consumption (Reynolds & Lowe, 1965) . Another naturalist observation reported that workers at a rubber parts plant exposed to tetramethylthiuram experienced the similar redness in the face, increased heart rate, and palpitations when consuming alcohol (Williams, 1937) . This led Williams to postulate: "If the chemical compound is not harmful to man, one wonders whether one had discovered the cure for alcoholism." During research attempting to treat intestinal worms, Erik Jacobsen and Jens Hald self-treated themselves with tetraethylthiuramdisulphide, and both men reported similar aversive symptoms (redness of the face, increased heart rate, sleepiness, etc.) following alcohol consumption. Additionally, Hald and Jacobsen (1948) subsequently indicated that blocking ALDH) resulted in a sharp increase in blood levels of ACD which in turn resulted in an increase in the aversive side effects of drinking (i.e. flushing of the skin, headaches, nausea, and shortness of breath). Tetraethylthiuramdisulphide has since been given the name disulfuram (marketed as antabuse) and was the first compound approved for the treatment of alcoholism by the US FDA.
While the exact physiological actions of the aforementioned compounds were not immediately clear, further research identified that they had a common mechanism of action in that they blocked the action of the enzyme ALDH which acts to break down ACD, the first metabolite of alcohol. Early research identified a direct relationship between alcohol consumption and blood ACD levels as Stotz (1943) reported that binge drinking episode (BEC 100-180 mg%) produced blood ACD levels 35 times higher than baseline levels. Similarly, blood ACD levels can be greatly augmented by antabuse treatment. In socially drinking individuals, treatment with antabuse increased blood ACD levels 5-10 fold compared to controls (Hald & Jacobsen, 1948; Larsen, 1948) . Additionally, antabuse treatment rendered ACD detectable in the breath of human participants following alcohol exposure (Hald & Jacobsen, 1948) . Animal research soon elucidated the metabolic pathway of EtOH and replicated the observation that ACD could be detected in the breath of rabbits receiving antabuse and alcohol (Hald et al., 1949a,b) .
Given the clinical implications of the early antabuse studies, several theories emerged associating alcoholism and ACD (Carpenter & MacLeod, 1952; Griffiths et al., 1974; Myers & Veale 1969; Truitt & Walsh, 1971) . The most strident theories suggested that ACD was responsible for all of the effects associated with alcohol and that alcoholism would be more appropriately termed acetaldehydism (Raskin, 1975; Truitt and Walsh, 1971) . Contrary studies suggested that ACD did not significantly mediate the effects of alcohol, and only trace amounts of ACD could be found in the cerebrospinal fluid or brain following alcohol consumption (Eriksson et al., 1980; Pikkarainen et al., 1979; Kiianmaa & Virtanen, 1978; Sippel, 1974) . These findings coupled with the observation that ACD could only cross the blood brain barrier at high concentrations (Eriksson, 1977; Petersen & Tabakoff, 1979; Sippel, 1974; Tabakoff et al., 1976) suggested that ACD could not and did not contribute to the behavioral or pharmacological effects of alcohol. Subsequent evidence of the local formation of ACD within the brain research rejuvenated the theory that ACD could mediate the biological effects of EtOH consumption (Cohen et al., 1980) .
Acetaldehyde Production in CNS
In the periphery, ACD is formed from EtOH through the action of alcohol dehydrogenase (ADH) primarily in the liver. In the brain, ADH is inactive (Zimatkin et al., 1998) , and formation of acetaldehyde from EtOH in the brain is achieved primarily through the action of another enzyme, catalase (Smith et al., 1997; Sippel, 1974; Zimatkin, 1991) . Originally, it was postulated that peripheral ACD was unlikely to enter the CNS due to the prevalence of ALDH and the blood-brain barrier (Hunt, 1996) . Further research indicated that high levels of peripherally administered ACD results in detection of ACD in the brain within minutes (Ward et al., 1997 ) Therefore, peripheral ACD may overwhelm the peripheral ALDH, allowing some percentage of ACD to enter the brain (Quertemont et al., 2005) . Additional local metabolic pathways (e.g. mitochondrial cytochrome P450) can also result in the formation of ACD from EtOH in the brain (Zakhari, 2006) . It is these non-ALDH metabolic pathways that produce the majority of ACD within the brain following EtOH consumption (Zimatkin et al., 1998) .
Acetaldehyde Reactivity
ACD is a highly reactive compound that reacts with several endogenous catecholamines to form biologically active compounds (Cohen, 1976; Cohen & Collins, 1970; Walsh et al., 1970) . With regards to research addressing alcohol use disorders, the compounds that have been of interest fall into two main classes: 1) the tetrahydroisoquinoline alkaloids (THIQs), which are formed through the direct and indirect interaction of ACD with monoamines (DA, epinephrine, and norepinephrine; Cohen, 1976) and 2) the tetrahydro-β-carbolines (TBCs), which are formed through the condensation of ACD with the indoleamines (tryptophan and tryptamine; Buckholtz, 1980) . The most commonly investigated THIQs, tetrahydropapaveroline (THP) and salsolinol (SAL), have been detected in the brain following the administration of alcohol (Weiner, 1980) . The TBCs have also received attention as to their underlying role in alcohol-associated behaviors and the physiological effects of alcohol; contradictory data on the actions of TBCs has been reported.
Alcohol, Acetaldehyde, and Acetaldehyde Products
Research studies have attempted to establish that ACD is a necessary component for the manifestation of the neurobiological and behavioral aspects of alcohol use disorders. Such studies have made use of compounds that inhibit the formation of ACD or sequester ACD into a stable non-reactive adduct. Early studies utilized the compound 3-amino-1,2,4-triazole (triazole), which inhibits brain catalase activity, halting the primary pathway for the breakdown of alcohol in the brain. Triazole administration decreased alcohol consumption in rats and mice (Aragon & Amit, 1992; Koechling & Amit, 1994) , reduced EtOH-related motor depression in rats (Aragon et al., 1985) , and EtOH-stimulated motor activity in mice (Escarabajal et al., 2000) . Triazole also decreased the intake of saccharin-quinine solution (Rotzinger et al., 1994) and food (Tampier et al., 1995) suggesting the compound could be causing non-specific effects unrelated to ACD formation as a result of alcohol exposure. Similar research has been completed using the compound D-penicillamine, which acts to sequester ACD into a non-reactive stable adduct but does not alter EtOH metabolism. Studies using D-penicillamine have established that sequestering ACD results in a reduction of alcohol intake and a decrease in alcohol conditioned place preference in rats Font et al., 2006b; Peana et al., 2008) . D-penicillamine also reduces alcohol conditioned place preference and alcohol induced motor depression in mice (Font et al., 2005; Font et al., 2006a) .
Research has focused on the contribution of the THIQs to physiological effects of alcohol and ACD. Early studies indicated that ACD acted to inhibit the metabolism of dopaldehyde alkaloid, which is formed from the condensation of dopamine and acetaldehyde, resulting in greater levels of THP . Central administration of low concentrations of THP into the lateral ventricles produced an increased preference and consumption of EtOH in rats and primates (McCoy et al., 2003; . Higher doses of THP resulted in decreased alcohol preference and consumption (Duncan & Deitrich, 1980) . Microinjections of lower doses of THP into regions in the mesolimbic reward pathway, including the VTA or the Acb, acted to increase EtOH alcohol preference in rats Duncan & Fernando, 1991) . Research has attempted to elucidate the neurochemical systems mediating the effects of THP on EtOH consumption . Buspirone (a 5-HT 1a receptor agonist) decreased the THP-stimulated augmentation of EtOH consumption (Privette et al., 1988) . Further research with THP has not been conducted.
Systemic administration of SAL increased EtOH consumption and preference . The ability of SAL to augment EtOH consumption is centrally mediated since microinjections of SAL into the lateral ventricle increased EtOH consumption and preference (Purvis et al., 1980) . Similar to ACD, research has indicated that SAL possesses reinforcing/rewarding properties. Peripherally administered SAL will condition a place preference (Matsuzawa et al., 2000) .
Compared to other ACD products, the neurochemical basis of SAL effects has been studied more intensively. SAL inhibits catecholamine reuptake (Alpers et al., 1975; Heikkila et al., 1971; Tuomisto & Tuomisto, 1973) and/or metabolizing enzymes such as catecholmethyltransferase and monoamine oxidase (Alpers et al., 1975; Collins et al., 1973) resulting in increases in catecholamine levels. SAL has been shown to significantly decrease striatal levels of 5-HT metabolic enzymes, subsequently increasing 5-HT to a levels 20 fold higher than DA (Nakahara et al., 1994) . Additionally, SAL has been shown to possess a high affinity for the μ (MOR) opioid receptor (Airaksinen et al., 1984) . SAL-induced locomotor activity, conditioned place preference, and stimulated DA release in the AcbSh can be reduced by microinjections of MOR antagonists into the posterior VTA (Hipolito et al, 2010 (Hipolito et al, , 2011 .
There has been less attention on the role of TBCs in alcohol use disorders compared to ACD or the THIQs. Initial studies indicated that acute peripheral administration of TBC derivatives acted to decrease the preference for alcohol over water in rats (Geller & Purdy, 1975; Geller et al., 1973; Messiha & Geller, 1976) . Chronic intra-cerebral ventricular (ICV) microinjections of the TBC tryptoline significantly increased alcohol preference and consumption (Adell & Myers, 1994; Airaksinen et al., 1983; Huttunen & Myers, 1987; Tuomisto et al., 1982) . Co-infusion of tryptoline and THP augmented alcohol preference and consumption in a synergistic nature (Myers & Oblinger, 1977) . Infusion of TBC into the hippocampus of low alcohol drinking (LAD) rats increased alcohol preference and consumption (Adell & Myers, 1995; Huttunen & Myers, 1987) through increases in both 5-HT and norepinephrine levels (Adell & Myers, 1995) . TBCs exhibit an affinity for the δ opioid receptor (DOR) (Airaksinen et al., 1984) , but the pharmacological properties of TBCs have not been fully examined.
Acetaldehyde is Pharmacologically Active in the CNS
ICV microinjections of ACD increased preference for and consumption of alcohol in rodents (Brown et al., 1979; . It was also discovered that ACD possessed reinforcing properties as rats would readily self-administer ACD through both ICV (Amit et al., 1977; Brown et al., 1979; Brown et al., 1980) and intra-venous (IV; Myers et al., 1984) routes. Animals receiving ICV infusions of ACD exhibited a conditioned place preference (CPP) associated with the drug (Smith et al., 1984) while peripheral injections of ACD induced a conditioned taste aversion similar to alcohol (Aragon et al., 1986) .
Central and peripheral administration of ACD produces a CPP in a variety of rat lines (Quintanilla & Tampier, 2003; Spina et al., 2010) . Quertemont and De Witte (2001) reported that rats showed a dose dependent stimulus preference when ACD was administered peripherally. Much like EtOH, ICV-administered ACD at lower doses, produced an elevation in locomotor activity in rats (Correa et al., 2003) , while peripheral and central administration of high doses of ACD produced motor depression in both rats and mice (Durlach et al., 1988; Holtzman & Schneider, 1974; Myers et al., 1987; Quertemont et al., 2004; Tambour et al., 2006) . Similar biphasic effects on locomotor activity have been observed following vapor exposure to ACD .
While there is still dispute over the extent to which ACD contributes to the neurobiological and behavioral actions of alcohol, emerging evidence indicates that ACD is biologically active and may mediate, in part, alterations in behavior produced by EtOH exposure/ consumption. Research has shown that both central and peripheral administration of ACD cause an increase in alcohol consumption in rats (Brown et al., 1979; . Rats will exhibit ACD induced CPP and stimulus preference suggesting that ACD is rewarding (Quertemont & De Witte, 2001; Quintanilla & Tampier, 2003; Smith et al., 1984; Spina et al., 2010) ; blocking or sequestering the formation of ACD resulting from alcohol exposure produces alterations in the neurobiological and behavioral effects of alcohol (Aragon & Amit, 1992; Diana et al., 2008; Font et al., 2005; Font et al., 2006a; Font et al., 2006b; Kaharanian et al., 2011; Koechling & Amit, 1994; Peana et al., 2008) . While it is currently difficult to assert that ACD is absolutely necessary for the neurobiological and behavioral actions of alcohol, data show that ACD is likely to be involved to some extent.
Acetaldehyde in the VTA -In vivo electrophysiology
ACD has excitatory actions on neurons of the VTA as clearly demonstrated by the effects on dopamine release and on the firing frequency of individual VTA neurons. In experiments using in vivo recording methods, ACD was injected intravenously at doses of from 5 to 40 mg/kg, and a dose-dependent increase in firing of dopaminergic VTA neurons was reported (Foddai et al., 2004) . Thus, ACD parallel the effects observed with EtOH, but at 50 times lower concentrations. The effects of EtOH on VTA neuronal activity was blocked by systemic pretreatment with the ADH inhibitor 4-methylpyrazole, but this drug had no effect on ACD-induced excitation (Foddai et al., 2004) , suggesting that the excitatory effects of EtOH on the VTA are mediated by ACD. The data also implicated that peripheral ACD formation (mediated by ADH) rather than central ACD formation (which would be mediated by catalase) was the basis of the finding. Sequestration of ACD by in vivo administration of D-penicillamine is sufficient to block the excitatory effects of intragastrically administered EtOH or intragastrically administered ACD (Enrico et al., 2009 ).
The clear effects of manipulation of acetaldehyde by a variety of methods (e.g., enzyme antagonism or acetaldehyde sequestration) indicate that this is a robust in vivo phenomenon, and the effect of EtOH on dopaminergic VTA neurons in vivo is dependent on acetaldehyde.
Acetaldehyde in the VTA -In vitro studies
Significant studies have been performed using brain slice preparations showing that acutely applied ACD can increase the firing frequency of dopaminergic VTA neurons. The key results of that study indicate that ACD-induced activation of dopaminergic VTA neurons mimics EtOH-induced excitation , and is produced at much lower concentrations (10-100 nM) compared to EtOH (typical excitatory concentrations of 20-120 mM; Brodie and Appel, 1998; Brodie et al., 1990) . Furthermore, EtOH applied in the presence of a catalase inhibitor, 3-aminotriazole (1 mM), failed to produce its characteristic excitation of the VTA neurons in this study. In exploring the mechanism of ACD excitation of VTA neurons, Melis et al. (2007) examined the effect of ACD on two ion currents, Acurrent and h-current. An A-current represents a rapidly-inactivating potassium current that can contribute to spike after hyperpolarization and is involved in the regulation of firing frequency of dopaminergic VTA neurons (Koyama and Appel, 2006a) . On the other hand, hcurrent is a characteristic current of dopaminergic VTA neurons that is activated at membrane potentials about 20 mV negative to the resting membrane potential; it may contribute to the spontaneous firing rate of dopaminergic VTA neurons from mice (Okamoto et al. 2006; McDaid et al. 2008) but not those from rats (McDaid et al. 2008; Appel et al. 2003) , but its major role is likely to be in the regulation of excitability and synaptic signal integration in dopaminergic VTA neurons (Inyushin et al. 2010) . The authors noted a rightward voltage shift produced by ACD on I A (Melis et al., 2007) . Also noted was a significant increase in h-current produced by acutely applied ACD; this is consistent with an effect of EtOH, which has been shown to acutely increase I h of VTA neurons in brain slices (Brodie and Appel, 1998; Okamoto et al., 2006) . In addition, the authors blocked ACD-induced excitation with two specific ion channel blockers: 4-aminopyridine (10 mM) which blocks A-current and ZD7288, which blocks h-current. Both agents apparently blocked the ACDinduced excitation of the VTA neurons (Melis et al., 2007) . The firing rate was increased by 4-aminopyridine alone, and no further increase in firing was observed with the addition of ACD. In contrast, ZD7288 (30 μM) alone reduced the firing rate of dopaminergic VTA neurons (as has been seen by some (Okamoto et al., 2006) but not others (Appel et al., 2003) , and no ACD-induced excitation was observed in the presence of ZD7288.
The most parsimonious model suggests that EtOH is metabolized to ACD by catalase locally in the VTA, and the authors of these studies suggest that, in general, EtOH actions on the VTA are mediated by ACD.
Differences in the action of acetaldehyde: Methodological considerations
It is an inherently unsatisfying argument to invoke methodological differences to explain contrary experimental results, but in the case of brain slice electrophysiology, often this is the underlying source of controversy. Variables such as ionic concentrations in external or internal media, purity of reagents, species, strain or supplier of subjects, and even plane of section, can alter the results and can lead to different conclusions among investigators. Controversies in the literature among investigators may not be amenable to resolution simply due to the multiplicity of unknown variables. Each laboratory achieves consistency of results by controlling many of these variables, but each may control these variables differently. With acetaldehyde, the differences among laboratories may become more extreme, as the reactivity and labile chemical nature of acetaldehyde may yield a null result, even when other variables are controlled. Parasaggital section of the midbrain may yield slices with relatively more intact glutamatergic fibers than coronal sections; ACD has been shown to interact with glutamatergic systems (Padilla-de la Torre et al., 2008) . There is ample evidence that ZD7288 reduces glutamate release as well as blocking h-current; if a portion of ACD effects were produced by actions on presynaptic glutamatergic endings in the VTA, differences in the viability of the glutamate terminals could explain differences in the effects of ACD and other agents.
Differences between acetaldehyde and alcohol: electrophysiological studies
While the results of these studies, especially those of the enzyme antagonist experiments, indicate that EtOH actions on the firing of mesolimbic dopaminergic neurons are mediated by ACD formed in the VTA, there are some clear differences in the mechanisms of action of the two agents. ACD-induced excitation of dopaminergic VTA neurons appears to be mediated by effects on h-current and A-current (Melis et al., 2007) . EtOH excitation in dopaminergic neurons of the rat has been shown to be blocked by quinidine, but not by blockers of h-current (Appel et al., 2003) . Furthermore, EtOH excites individual VTA neurons dissociated from brain slices (Brodie et al., 1999; Ye et al., 2001 ), a preparation that would be expected to reduce the ability of synthesized ACD to act on these independent VTA neurons, and the concentration-response for EtOH excitation of dissociated dopaminergic VTA neurons (Brodie et al., 1999 ) is similar to that observed in brain slices (Brodie et al., 1990) .
Clearly, the results of Melis, et al indicate that ACD affects both A-current and h-current, but these effects are not consistent with an EtOH-like action. Acute (Brodie and Appel, 1998) and chronic (Okamoto et al., 2006) EtOH has clear effects on h-current, and it suggests that some of the effects of EtOH on firing frequency should be mediated by h-current. Despite the finding in one study that suggested that EtOH excitation of dopaminergic VTA neurons of mice could be blocked with ZD7288 (Okamoto et al., 2006) , additional studies of this phenomenon indicate that apparent reduction of EtOH excitation was more likely due to effects of ZD7288 that are not related to its action on h-channels (McDaid et al., 2008) . The role of h-current in modulating the firing frequency of dopaminergic neurons of the VTA may differ in different preparations and in different rodents, as ZD7288 alone produces a decrease in firing rate in some studies (Melis et al., 2007; Okamoto et al., 2006) , but not in others (Appel et al., 2003) except at high concentrations (Seutin et al., 2001) . Under conditions and in species in which ZD7288 does not affect the firing rate, it also does not affect EtOH action. The action of ZD7288 and other blockers of ion channels may depend on specific experimental conditions (see above).
One agent that has been shown to decrease EtOH excitation in rat dopaminergic VTA neurons is quinidine (Appel et al., 2003 ), which was not tested against ACD-induced excitation. EtOH also decreases M-current (Koyama et al., 2007) , and the effect of ACD on M-current is unknown. M-current is a voltage dependent, sustained potassium current that affects the firing frequency of dopaminergic VTA neurons (Koyama and Appel, 2006b) . A study of the effects of EtOH on the ion channel responsible for M-current is one example of the difficulty in cataloging the effects of agents on ionic currents and then postulating a functional role for those currents on cell activity. EtOH reduces M-current of dopaminergic VTA neurons in a concentration-dependent manner (Koyama et al., 2007) , but the selective M-current blocker XE-991 did not significantly reduce EtOH-induced excitation (Koyama et al., 2007) . The effects of EtOH on M-current may be physiologically important in some processes, (for example, adaptation to chronic EtOH exposure), modulation of M-current does not alter the acute excitatory effect of EtOH.
The data indicate the EtOH and ACD are not producing the same electrophysiological effects on VTA DA neurons, but the results of studies indicating the lack of an EtOH effect on dopaminergic neurons in the presence of antagonists of ADH (Foddai et al., 2004) or catalase (Melis et al., 2007; Diana et al., 2008) are compelling, and suggest that the metabolism of EtOH to ACD mediate EtOH-induced excitation in dopaminergic VTA neurons. It seems most likely that ACD is a crucial component of the overall effects of EtOH on dopaminergic neurons of the VTA; the essential action of ACD could be parallel to EtOH, or it could enhance EtOH-induced changes. Blockade of the formation of ACD can reduce the response of dopaminergic VTA neurons to EtOH, and could serve as a platform for development of agents that reduce the rewarding and reinforcing actions of EtOH.
Behavioral Pharmacology of Acetaldehyde within the Mesolimbic Dopamine System
Despite the inconsistent electrophysiological studies, the results of behavioral pharmacological research examining the affects of acetaldehyde within the mesolimbic dopamine (VTA and nucleus accumbens) have been relatively consistent. EtOH, ACD, and SAL are directly self-administered into the posterior, but not anterior, VTA (Rodd et al., 2008 Rodd-Henricks et al., 2002) . Self-administration of all 3 compounds into the posterior VTA can be extinguished by co-administrations of quinpirole, a D 2 receptor agonist (Rodd et al., , 2008 . Thus, the reinforcing actions of all 3 compounds in the posterior VTA is dependent upon VTA DA neuronal activity, since quinpirole would act to stimulate D 2 autoreceptors (reduction in DA activity). SAL microinjected into the VTA will produce a conditioned place preference (Hipolito et al., 2010 (Hipolito et al., , 2011 . Reverse microdialysis of SAL has been shown to modulate DA levels within the Acb (Hipolito et al., 2009) . EtOH and SAL self-administration, but not ACD, directly into the posterior VTA is extinguished by co-administration of 5HT receptor antagonists (Rodd et al., , 2008 . EtOH has direct actions on 5HT 3 receptors (Lovinger and White, 1991) and SAL can increase the release of 5HT (Maruyama et al., 1992 (Maruyama et al., , 1993 , but ACD does not express an affinity for 5HT 3 receptors (Li, 2000) .
Examining the concentration of SAL, ACD, and EtOH required to support selfadministration directly into the posterior VTA provides an indication of the efficacy between the compounds. EtOH is typically self-administered between the ranges of 20-80 mM directly into the posterior VTA (Rodd et al., 2003 . ACD is reinforcing between 6-90 μM, while SAL is self-administered between 0.03-0.3 μM directly into the posterior VTA (Rodd et al., , 2008 . Thus, the concentration required for SAL to support selfadministration into the posterior VTA is 200-fold less than that required for ACD and 300 × 10 3 lower than EtOH. All of these concentrations are within the range observed in the brain following oral consumption of EtOH (Haber et al., 1997 , Zimatkin et al., 1998 , and are thus pharmacologically relevant.
In addition, the dose response curves of the 3 compounds would support the stance that EtOH is possibly a pro-drug. However, EtOH self-administration directly into the posterior VTA is not altered by co-administration of a catalase antagonist (3-amino-1,2,4-triazole; triazole; Rodd et al., 2005 ). Yet, ACD could have been produced within the posterior VTA following self-infusion of EtOH through a catalase-independent pathway. A more recent study has examined the possible role for ACD in the etiology of alcohol use/abuse through the use of lentiviral vectors that decrease catalase activity or increase ADH activity in the VTA (Kaharanian et al., 2011) . Administration of either lentiviral vector into the VTA acted to decrease voluntary consumption of EtOH as well as EtOH stimulated DA release in the AcbSh suggesting that the breakdown of EtOH into ACD is a component of EtOH reward (Kaharanian et al., 2011) . A later study replicated such findings in that an anti-catalase viral vector was once again successful in decreasing EtOH intake in naïve rats . However, the anti-catalase viral vector was only successful at decreasing EtOH consumption, in animals that had previous access to EtOH over the course of 60 days, following a period of imposed abstinence (i.e. during relapse; Quintanilla et al., 2011) .
The ability of a compound to stimulate VTA DA neurons can also be measured by determining the effects of compounds directly applied to the VTA on DA release in downstream projection areas. The effects of DA release in the Acb following microinjections of drugs into the VTA have been examined for EtOH, ACD, and ACD products. Myers & Robinson (1999) were first to report that THP microinjected into the anterior VTA had a direct effect on DA release in the Acb. Further, THP was detected in vivo in the striatum (Haber et al., 1997) and Acb (Baum et al., 1999) showing that THP could be formed in the brain within structures involved in drug reward.
Recent studies have utilized the same equipment employed for intracranial selfadministration studies to determine the effects of microinjection of a compound into the posterior VTA on DA levels in the AcbSh. Microinjections of 200 mg% EtOH (optimal concentration) into the posterior VTA increased DA levels in the AcbSh (Ding et al., , 2011 . Similar to the intracranial self-administration data, lower concentrations of ACD (23 μM) and SAL (0.3 μM) microinjected into the posterior VTA were able to evoke dopamine release in the AcbSh (Deehan et al., in press) . The data sets also reveal that SAL was able to increase DA levels in the AcbSh at a greater amount than EtOH (Fig. 2) . Therefore, there were parallel findings between the concentration required to produce reinforcement and that required to stimulate VTA DA neurons and evoke DA release in the AcbSh.
The research examining the effects of SAL and ACD in other brain regions has lagged behind that conducted in the VTA. Both EtOH and SAL are self-administered into the AcbSh, but not AcbC Rodd et al., 2003) . Similar to the VTA data set, SAL was self-administered into the AcbSh at significantly (400 × 10 3 ) lower concentrations than EtOH. Both EtOH and SAL self-administration into the AcbSh could be extinguished by co-administration of a D 2/3 antagonist (sulpiride). Therefore, the reinforcing properties of both SAL and EtOH within the AcbSh are dependent upon activation of postsynaptic DA receptors. The reinforcing properties or neurochemical effects of EtOH, SAL and ACD in other brain regions (e.g., medial prefrontal cortex or central amygdala) have not been extensively studied.
General Summary
The current literature indicates that the reinforcing properties, and the behavioral consequences, of EtOH are mediated, in part, by ACD and ACD products (SAL). In general, the data reflect the complexity of EtOH within the CNS. There is evidence that EtOH can directly act at receptors and to stimulate VTA DA neurons (Brodie et al., 1999; Ye et al., 2001; Lovinger and White, 1991) . Convergent evidence that both ACD and SAL have distinct actions within the mesolimbic dopamine system has recently been reported. Additional studies have indicated that EtOH consumption and reinforcement may be mediated by the conversion of EtOH into ACD. The following statements are supported by current research; 1) EtOH can have direct actions to produce neurochemical, electrophysiological, and behavioral consequences, 2) some of EtOH's actions may be mediated by, in part, the conversion of EtOH into ACD, 3) ACD in the CNS has reinforcing properties which are mediated by the mesolimbic dopamine system, 4) products derived from ACD can also produce reinforcement within the mesolimbic dopamine system, 5) the actions of EtOH, ACD, and SAL within the mesolimbic dopamine system can occur at physiologically relevant levels, and 6) whole areas of research about the EtOH-ACD-SAL system has not been elucidated. Ultimately, the sequelae of alcoholism may be based upon a complex series of interwoven peripheral and central effects of EtOH and its metabolites. It is perhaps our lack of understanding of this complex system that has prevented the development of successful pharmacotherapeutics for the treatment of alcoholism. 
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